Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
3
×
biotech
boston blog main
cancer
indiana blog main
indiana top stories
new york blog main
new york top stories
type 1 diabetes
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
alopecia areata
amarin
amgen
andrew berens
aridis pharmaceuticals
aristea therapeutics
autoimmune diseases
avapritinib
axitinib
bellus health
biotech ipos
blueprint medicines
boehringer ingelheim
bolt biotherapeutics
boston
boston top stories
boulder/denver blog main
boulder/denver top stories
bridgebio
bristol-myers squibb
cell therapy
cidara therapeutics
What
drug
type
3
×
approval
fda
patients
advantages
announced
bar
bid
bio
blueprint
boehringer
brings
cancer
chasing
deadly
deciphera
diabetes
eli
expand
expect
fallen
filing
forms
gamble
gi
ingelheim
lilly
market
marketed
medco’s
medicine
medicine’s
morning
mover
new
payers
pharamceuticals
physicians
plan
Language
unset
3
×
Current search:
type
×
unset
×
" national blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug